Skyline Medical Inc. is a medical device company that develops and manufactures The STREAMWAY System, a solution for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company distributes these products to hospitals, surgical centers and other medical facilities where bodily and irrigation fluids produced during surgical procedures must be contained, measured, documented and disposed. The Company also manufactures and sells two disposable products required for system operation: a bifurcated single procedure filter and tissue trap, and a single use bottle of cleaning solution. Both items are used on a single procedure basis. Its STREAMWAY Automated Surgical Fluid Waste Management System (FMS) is a wall mounted automated system that disposes of an unlimited amount of suctioned fluid from the patient using standard surgical tubing. The FMS suctions surgical waste fluid from the patient using standard surgical tubing.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:SKLN
- CUSIP: N/A
- Web: www.skylinemedical.com
- Market Cap: $9.9 million
- Outstanding Shares: 6,189,000
- 50 Day Moving Avg: $1.54
- 200 Day Moving Avg: $2.01
- 52 Week Range: $1.31 - $6.75
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $534,756.00
- Price / Sales: 18.52
- Book Value: $0.61 per share
- Price / Book: 2.62
- EBIDTA: ($4,590,000.00)
- Net Margins: -1,063.93%
- Return on Equity: -400.36%
- Return on Assets: -174.33%
- Current Ratio: 4.07%
- Quick Ratio: 3.88%
- Average Volume: 372,603 shs.
- Beta: 0.14
- Short Ratio: 1.41
Frequently Asked Questions for Skyline Medical (NASDAQ:SKLN)
What is Skyline Medical's stock symbol?
Skyline Medical trades on the NASDAQ under the ticker symbol "SKLN."
How were Skyline Medical's earnings last quarter?
Skyline Medical Inc. (NASDAQ:SKLN) issued its earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $0.18 million for the quarter. Skyline Medical had a negative net margin of 1,063.93% and a negative return on equity of 400.36%. View Skyline Medical's Earnings History.
Who are some of Skyline Medical's key competitors?
Some companies that are related to Skyline Medical include Xtant Medical Holdings (XTNT), Advanced Oncotherapy PLC (AVO), Sphere Medical Holding PLC (SPHR), PhotoMedex (PHMD), Dextera Surgical (DXTR), BIOLASE (BLTI), Cynosure (CYNO), Derma Sciences (DSCI), Hansen Medical (HNSN), Lifeline Scientific (LSIC), Mindray Medical International Ltd (MR), Nanosphere (NSPH), Sirona Dental Systems (SIRO), Synergetics USA (SURG), Thoratec (THOR), Volcano Corp (VOLC) and Zeltiq Aesthetics (ZLTQ).
Who are Skyline Medical's key executives?
Skyline Medical's management team includes the folowing people:
- Carl Schwartz, President, Chief Executive Officer, Director
- Robert L Myers, Chief Financial Officer
- David O Johnson, Chief Operating Officer
- J. Melville Engle, Director
- Richard L. Gabriel, Director
- Ricardo Koenigsberger, Director
- Timothy A. Krochuk, Director
- Frank G. Mancuso Jr., Director
How do I buy Skyline Medical stock?
Shares of Skyline Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Skyline Medical's stock price today?
MarketBeat Community Rating for Skyline Medical (NASDAQ SKLN)MarketBeat's community ratings are surveys of what our community members think about Skyline Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Skyline Medical stock can currently be purchased for approximately $1.60.
Consensus Ratings for Skyline Medical (NASDAQ:SKLN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Skyline Medical (NASDAQ:SKLN)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Skyline Medical (NASDAQ:SKLN)Earnings History by Quarter for Skyline Medical (NASDAQ SKLN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/15/2017||Q1 2017||($0.21)||$0.18 million||View||N/A|
|11/15/2016||Q3 2016||($0.32)||$0.14 million||View||N/A|
Earnings Estimates for Skyline Medical (NASDAQ:SKLN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Skyline Medical (NASDAQ:SKLN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Skyline Medical (NASDAQ:SKLN)
Insider Ownership Percentage: 10.79%Insider Trades by Quarter for Skyline Medical (NASDAQ:SKLN)
Institutional Ownership Percentage: 5.80%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/3/2014||Samuel Herschkowitz||Major Shareholder||Buy||210,680||$0.11||$23,174.80|| |
|9/15/2014||Robert L Myers||CFO||Buy||5,000||$0.13||$650.00|| |
|8/27/2014||David O Johnson||COO||Buy||14,300||$0.14||$2,002.00|| |
|8/22/2014||Robert L Myers||CFO||Buy||5,000||$0.15||$750.00|| |
|8/19/2014||Samuel Herschkowitz||Major Shareholder||Buy||2,000||$0.12||$240.00|| |
|7/23/2014||Samuel Herschkowitz||Major Shareholder||Buy||25,000||$0.13||$3,250.00|| |
|7/14/2014||Samuel Herschkowitz||Major Shareholder||Buy||6,200||$0.13||$806.00|| |
|5/22/2014||Samuel Herschkowitz||Major Shareholder||Buy||66,000||$0.13||$8,580.00|| |
|4/30/2014||Samuel Herschkowitz||Major Shareholder||Buy||61,500||$0.13||$7,995.00|| |
|3/27/2014||Samuel Herschkowitz||Major Shareholder||Buy||21,812||$0.19||$4,144.28|| |
|3/18/2014||Samuel Herschkowitz||Major Shareholder||Buy||23,000||$0.21||$4,830.00|| |
|12/13/2013||Arnon I Dreyfuss||Director||Buy||5,021||$0.24||$1,205.04|| |
|11/26/2013||Samuel Herschkowitz||Major Shareholder||Buy||10,000||$0.29||$2,900.00|| |
|11/25/2013||Arnon I Dreyfuss||Director||Buy||25,000||$0.27||$6,750.00|| |
|11/20/2013||Samuel Herschkowitz||Major Shareholder||Buy||25,500||$0.28||$7,140.00|| |
|8/16/2013||Samuel Herschkowitz||Major Shareholder||Buy||23,000||$0.21||$4,830.00|| |
|8/6/2013||Arnon I Dreyfuss||Director||Buy||20,000||$0.22||$4,400.00|| |
Headline Trends for Skyline Medical (NASDAQ:SKLN)
Latest Headlines for Skyline Medical (NASDAQ:SKLN)
Skyline Medical (SKLN) Chart for Saturday, July, 22, 2017